Cannabis Stocks to Watch in 2026: Rescheduling Could Unlock a $2.3 Billion Tax Break

The cannabis investment landscape is entering what many analysts consider its most consequential year since legalization began sweeping across states over a decade ago. President Trump's December 2025 executive order directing the attorney general to expedite marijuana rescheduling from Schedule I to Schedule III [Quick Definition: A mid-level federal drug classification including ketamine and testosterone] has injected fresh optimism into a sector that has spent the better part of three years in a brutal downturn. If rescheduling is finalized, the U.S. cannabis industry could see a collective $2.3 billion tax break — potentially transforming companies that have been bleeding cash into profitable enterprises virtually overnight.

But the cannabis stock market remains one of the most volatile and unpredictable corners of investing. Understanding which companies are positioned to benefit most, and which risks remain, is essential for anyone considering exposure to this sector in 2026.

Key Takeaways

Federal rescheduling to Schedule III could save the cannabis industry $2.3 billion in taxes by eliminating the 280E [Quick Definition: IRS code barring cannabis businesses from deducting normal expenses like rent and payroll] penalty.

Village Farms International has surged 371% on booming international medical cannabis demand.

Green Thumb Industries and Trulieve Cannabis lead the sector with consistent profitability and dominant market positions.

The 280E Problem: Why Rescheduling Changes Everything
Top Cannabis Stocks to Watch
The Investment Case: What Could Go Right
The Risks: What Could Go Wrong
ETFs: A Lower-Risk Way to Play

The 280E Problem: Why Rescheduling Changes Everything

At the heart of the cannabis investment thesis is Section 280E [Quick Definition: IRS code barring cannabis businesses from deducting normal expenses like rent and payroll] of the Internal Revenue Code. This provision, originally designed to prevent drug traffickers from writing off business expenses, has been applied to legal cannabis companies since they traffic in a Schedule I substance under federal law. The practical effect is devastating: cannabis businesses cannot deduct most ordinary business expenses — rent, payroll, marketing, utilities — from their taxable income.

The result is effective tax rates that can exceed 70% for plant-touching cannabis companies. In an industry already struggling with oversupply and price compression, 280E has been a financial straitjacket. Major multistate operators [Quick Definition: Cannabis companies licensed in multiple states] collectively owe more than $1.6 billion in back taxes to the IRS, according to recent public filings.

Moving cannabis to Schedule III would eliminate the 280E burden entirely. Cannabis retailers in higher-volume states like Maryland could save an average of $805,000 annually per store. For large multistate operators with hundreds of locations, the savings run into the hundreds of millions.

Trulieve's chief financial officer has publicly stated that removing 280E could result in "hundreds of millions" in savings for the company alone.

Top Cannabis Stocks to Watch

Green Thumb Industries (GTBIF)

Green Thumb Industries stands out as one of the most fundamentally sound cannabis companies in the public markets. Operating more than 100 retail dispensaries and 20 manufacturing facilities across 14 states, it is one of the few cannabis stocks that has been consistently profitable on an annual basis since 2020.

In an industry littered with companies burning through cash and issuing dilutive shares to stay afloat, Green Thumb's financial discipline is rare. The stock is one of the few cannabis names in positive territory over the past five years — a modest gain of roughly 1%, but remarkable in a sector where many peers have lost 80% or more of their value.

Green Thumb's diversified footprint across established and emerging markets gives it resilience against any single state's regulatory or pricing challenges. If rescheduling delivers the tax relief investors expect, Green Thumb's already positive margins could expand dramatically.

Trulieve Cannabis (TCNNF)

Trulieve is the largest cannabis retailer in America, with more than 230 stores across nine states and 15 processing facilities in six states. The company dominates Florida's medical market and holds leading positions in Arizona and Pennsylvania.

Year-to-date through Q3 2025, Trulieve reported $888 million in revenue, $214 million in operating cash flow, and a 60% gross margin. It also completed payment on $368 million in debt — a signal that management is preparing the balance sheet for a new era. As the largest direct-to-consumer cannabis retailer, Trulieve stands to capture an outsized share of the 280E savings.

Curaleaf Holdings (CURLF)

Curaleaf operates one of the broadest cannabis footprints in the country and has been expanding internationally, including into European medical markets. While the company has faced more profitability challenges than Green Thumb or Trulieve, its scale positions it as a major beneficiary of any federal policy shift.

Village Farms International (VFF)

Village Farms has emerged as one of the year's standout performers, with its stock skyrocketing 371% year-to-date as of early 2026. The company's medical cannabis export sales surged 758% year over year in Q3, driven by booming demand in Germany and expanding traction across other international markets.

Village Farms represents a different kind of cannabis bet — one focused on international medical markets rather than U.S. retail. For investors looking for geographic diversification within the cannabis sector, it offers an interesting alternative.

WM Technology / Weedmaps (MAPS)

Weedmaps operates the leading online cannabis marketplace and B2B platform for licensed retailers. Unlike plant-touching companies, Weedmaps is not directly burdened by 280E — but it benefits enormously from a healthier overall industry. If rescheduling drives more dispensary openings, higher marketing budgets, and increased consumer traffic, Weedmaps' advertising and technology revenue should follow.

The Investment Case: What Could Go Right

Several catalysts could drive cannabis stocks higher in 2026. The most obvious is the completion of rescheduling. ATB Capital Markets forecasts 4% revenue growth for multistate operators in 2026, with mergers and acquisitions potentially providing additional momentum in the second half of the year.

The broader market backdrop is also shifting. The U.S. cannabis industry is expected to approach $47 billion in 2026. Support for legalization sits at 87% nationally.

More states are either launching new programs (Alabama, Virginia) or expanding existing ones (Georgia). And the industry is consolidating — weaker operators are exiting, leaving survivors with better pricing power and market share.

For investors, the consolidation phase could be the most interesting dynamic. Companies with strong balance sheets and operational discipline are acquiring distressed competitors at steep discounts, building scale that should pay dividends when the regulatory environment improves.

The Risks: What Could Go Wrong

Cannabis investing remains high-risk for several important reasons.

First, rescheduling is not guaranteed. While political momentum is strong, the administrative process is complex and could face legal challenges. Any delay or reversal would likely trigger sharp selloffs in cannabis stocks.

Second, major banks remain on the sidelines. Moving cannabis to Schedule III does not equal legalization, and most large financial institutions will not provide banking services to cannabis companies until explicit safe harbor legislation — like the SAFER Banking Act — passes Congress. Limited banking access constrains growth, increases operational costs, and prevents many institutional investors from participating in the sector.

Third, oversupply and price compression continue to plague the industry. The total number of active cannabis business licenses in the U.S. has fallen 13% over the past two years, with cultivation licenses dropping 24%. Retail cannabis flower discounts averaged 39% in Washington state.

Until supply and demand rebalance, profitability will remain elusive for many operators.

Fourth, most cannabis stocks trade on over-the-counter (OTC) markets with limited liquidity and less regulatory oversight than major exchanges. Single political statements can cause double-digit price swings in a day. Investors need strong stomachs.

ETFs: A Lower-Risk Way to Play

For investors who believe in the cannabis thesis but want to diversify away from single-stock risk, cannabis ETFs offer broader exposure. The AdvisorShares Pure US Cannabis ETF (MSOS) holds a basket of top U.S. multistate operators and ancillary companies. The ETFMG Alternative Harvest ETF (MJ) provides a mix of U.S. and international cannabis exposure.

ETFs spread risk across multiple companies and can cushion against the kind of individual stock blowups that are common in early-stage industries. They're also more accessible through standard brokerage accounts than many individual cannabis stocks.

Pull-Quote Suggestions:

"Year-to-date through Q3 2025, Trulieve reported $888 million in revenue, $214 million in operating cash flow, and a 60% gross margin."

"If rescheduling is finalized, the U.S. cannabis industry could see a collective $2.3 billion tax break — potentially transforming companies that have been bleeding cash into profitable enterprises virtually overnight."

"Major multistate operators collectively owe more than $1.6 billion in back taxes to the IRS, according to recent public filings."

Why It Matters: Federal rescheduling could save cannabis companies $2.3B in taxes. Here are the top marijuana stocks to watch in 2026 and what investors need to know.